FindTrial
Sign In

Post-marketing re-evaluation of epunamin in the treatment of relapsed/refractory multiple myeloma in the post-new drug era

Post-marketing re-evaluation of epunamin in the treatment of relapsed/refractory multiple myeloma in the post-new drug era

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113803
Enrollment
Unknown
Registered
2025-12-03
Start date
2025-12-03
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Observation group for Multiple myeloma treatment:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Agree to participate in this study and sign a written informed consent form 2. Age >=18 years old, gender not limited; 3. Patients with relapsed or refractory multiple myeloma (RRMM) who have previously received systemic treatment regimens of lenalidomide or pomalidomide; 4. The expected survival period is over 6 months.

Exclusion criteria

Exclusion criteria: 1. Subjects with known or suspected hypersensitivity to any component of Aponermin , or with allergy or intolerance to thalidomide or dexamethasone.? 2. Pregnant women, women planning a pregnancy, or lactating women.? 3. Patients concurrently participating in other clinical studies. 4. Any other condition deemed by the investigator as unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Objective Response Rate;—

Countries

China

Contacts

Public ContactZhang Li

West China Hospital, Sichuan University

drzhangli2014@sina.com+86 28 8555 3329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026